KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenet Healthcare (THC) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Tenet Healthcare (THC) over the last 17 years, with Q4 2025 value amounting to -$434.0 million.

  • Tenet Healthcare's Cash from Financing Activities fell 1666.67% to -$434.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.4 billion, marking a year-over-year increase of 3484.4%. This contributed to the annual value of -$2.4 billion for FY2025, which is 3484.4% up from last year.
  • Per Tenet Healthcare's latest filing, its Cash from Financing Activities stood at -$434.0 million for Q4 2025, which was down 1666.67% from -$323.0 million recorded in Q3 2025.
  • Tenet Healthcare's 5-year Cash from Financing Activities high stood at $1.2 billion for Q4 2021, and its period low was -$2.7 billion during Q1 2024.
  • Its 5-year average for Cash from Financing Activities is -$491.9 million, with a median of -$347.5 million in 2024.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 135612.24% in 2021, then plummeted by 94352.94% in 2024.
  • Tenet Healthcare's Cash from Financing Activities (Quarter) stood at $1.2 billion in 2021, then tumbled by 137.77% to -$465.0 million in 2022, then skyrocketed by 31.83% to -$317.0 million in 2023, then fell by 17.35% to -$372.0 million in 2024, then fell by 16.67% to -$434.0 million in 2025.
  • Its last three reported values are -$434.0 million in Q4 2025, -$323.0 million for Q3 2025, and -$996.0 million during Q2 2025.